Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Current Clinical Trials at the ACTU

November 11, 2002

HPV and HIV in Women

HPV is a major cause of changes in the cervix. These changes are much more common in women with HIV and could lead to cancer of the cervix. The AIDS Clinical Trials Unit (ACTU) is running a trial on HIV and HPV that attempts to find out whether taking anti-HIV drugs will affect HPV in persons who have just started Highly Active Antiretroviral Therapy (HAART) for the first time. The study will run for 3-5 years. Study visits will include pap smears, brief pelvic exams, and colposcopy if needed. Volunteers will also be compensated $20 per study visit.

Call the ACTU at 206.731.3184 for further details. Ask for Lori or Alyssa and mention you are calling about study #5029.


Direct Observation Therapy for People With No Experience Taking Anti-HIV Drugs

Advertisement
The ACTU offers a new and interesting trial called Direct Observational Therapy study (DOT). This study looks at three different groups of people who no experience taking HIV medications. The goal is to see if taking medications under the direct supervision of a health care provider improves therapy results when compared with groups of people who take anti-HIV medications with minimal or no supervision.

This study will run for about 1 year and will provide medications to all three groups. Participants will be compensated $20 for each study visit plus $5 for DOT encounter.

For more detail and specific eligibility call the ACTU at 206.731.3184 and ask to speak with Lori or Alyssa about study #5073.


Therapeutic Drug Monitoring

This study will look at measuring the levels of Protease Inhibitors in the blood. The idea is to measure how much of a drug is in the blood and determine if the adjustments of these levels can help improve effectiveness of treatment. Participants would have to be experiencing a decline in the effectiveness of their second, third, or fourth anti-HIV regimen and have taken their current anti-HIV treatment for at least 12 weeks. Participation in this study can be from 4-48 weeks. There is a $20 per-visit compensation for all those enrolled in this trial.

You can get more information on this study by calling the ACTU at 206.731.3184. Ask for Lori or Alyssa and mention study # 5146.




  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
 
See Also
Washington
Advertisement:
Find out how a Walgreens specially trained pharmacist can help you

Tools
 

Advertisement